Keep Testing the Waters
To the Editor:
We have read with interest the article by Costa a profound selection, with exclusion of 48% of the patients who undenvent a thoracocentesis during the study because they did not comply with the conditions of the protocol, seems not to be justified given the prospective character of the study. Even among the remaining 288 patients, 108 (38%) were later excluded because they had more than one disease or an absence of a definitive diagnosis. These percentages of exclusion are much higher than in previous studies (11 to 18%),1-3 and they may convey a bias from overselection. Regardless ofthis, these high percentages of exclusion do limit the usefulness of the test. In fact, what will be the utility of the initial categorization of a pleural effusion as a transudate or an exudate in the absence of a definitive diagnosis at the end of the study?
for distinguishing between pleural exudates and transudates.
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We fully agree that because of the remarkable differences between groups, validation through a new series is needed, but it would be necessary to followv uniform criteria for diagnosis and procedures, which are not easy to agree upon when the authors are working apart. There is, however, a possibility that a meta-analysis, which is being conducted by Dr. John E. Heffner (personal communication, November 20, 1995) from the University of Arizona, may provide some guidelines on the matter.
In spite of the risk of overselection as a consequence of strict protocol requirements, we believe that there is no alternative when evaluating the accuracy of a test. For the application of the evaluated test to a clinical setting, less rigid diagnostic criteria are justified and the simultaneous consideration ofother factors such as age, presence of other symptoms and signs, evolutive pattern, etc, generally permit a sufficient degree of certainty for bacldng up clinical decisions.
